Molecular biologist @UMNews, Hormel Institute studying #lungcancer & vascular biology. Associate Professor, Husband, Father of 4, Runner, @MLB fan.
Minnesota, USA
Joined June 2016
- Tweets1K
- Following2.1K
- Followers751
- Likes6.7K
Luke Hoeppner retweeted
BREAKING: Rep. Thomas Massie has joined 26 other elected officials and 45 candidates in publicly stating the COVID shots must be pulled off the market.
Luke Hoeppner retweeted
Things I didn’t know before I was diagnosed w Stage IV #lungcancer in Nov 2022
1. For many (like me) 1st symptom was persistent cough. When that’s case, initial tumor has likely spread.
2. To qualify for CT lung cancer screening, you had to smoke a pack a day for 20 yrs.
Luke Hoeppner retweeted
JAK-STAT inhibition reduces endothelial pro-thrombotic activation and leukocyte- endothelial pro-adhesive interactions
Joan D Beckman, Angelica DaSilva, Elena Aronovich,..., Gregory M Vercellotti, Brian Betts, David K Wood
pubmed.ncbi.nlm.nih.gov/3673…
Luke Hoeppner retweeted
Great news: Funding bill has been approved by the senate. Here is what's in it:
NIH: $47.5 billion (+5.1%)
NSF: $9.87 billion (+11.7%)
NASA Science: $7.8 billion (+2.4%)
DOE’s Office of Science: $8.1 billion (+8.4%)
ARPA-H: $1.5 billion
Yeah!
Luke Hoeppner retweeted
Hadn't realized that the ApE plasmid editing software was now published! Congratulations to @ApEplasmid - everyone should use it and, now, cite it!
frontiersin.org/articles/10.…
Luke Hoeppner retweeted
Massive news: eLife to abolish accept/reject decisions: papers will just be “peer reviewed”. Others can argue about this, but lots of interesting consequences. 1/9 elifesciences.org/articles/8…
Luke Hoeppner retweeted
Our lab’s paper “SARS-CoV-2 disrupts host epigenetic regulation via histone mimicry” is out today in Nature! rdcu.be/cWXAV with a News and Views here nature.com/articles/d41586-0… a 🧵
Luke Hoeppner retweeted
Congrats to all new @ACS_Research @AmericanCancer Research Scholars! Wonderful to see the positive posts on #SciTwitter today 👊🏼 #cancerresearch
Luke Hoeppner retweeted
Zebrafish Avatars of rectal cancer patients validate the radiosensitive effect of metformin frontiersin.org/articles/10.…
We show that MET constitutes a promising less toxic alternative to the standard 5FU, which could be game changing in elderly/frail patients for tumor regression!
Luke Hoeppner retweeted
Although #zebrafish do not have lungs, they can get #tuberculosis by infection w/ the fish pathogen, Mycobacterium marinum. This is closely related to the human pathogen, Mycobacterium tuberculosis. For more info, check out this primer: ncbi.nlm.nih.gov/pmc/article… #ZebrafishFunFacts
ALT Image of a transgenic zebrafish larva (with neutrophils labelled in green) that has been injected with mycobacterium marinum (red). Image credit to Annemarie Meijer.
Luke Hoeppner retweeted
That story was so much fun. When we first saw the chordino and no tail MO results, I mailed packages of unlabeled solutions to 5 labs and told them to inject ~3nl and tell me what they saw. The winner was Randy Moon who called us back in 48 hours asking what we had given him…
Luke Hoeppner retweeted
Just submitted (finally!) our manuscript on making floxed alleles in #zebrafish, so we posted on bioRxiv as well. A truly herculean effort from Masahiro on this one! biorxiv.org/content/10.1101/…
Luke Hoeppner retweeted
PLCβ2 is a novel regulator of VEGF-induced vascular permeability and apotential therapeutic target for pathological permeability ahajrnls.org/3aVTTLE @HoeppnerLab @kphoenix
Luke Hoeppner retweeted
The conclusion of a 6 year passion project across @dukeMGM @tobinlab @centenaryinst @idlabs_astar: vascular leakiness drives neutrophil infiltration + excludes T cells from #zebrafish mycobacterial granulomas. Published in @FEMSmicro Pathogens & Disease doi.org/10.1093/femspd/ftac0…
Luke Hoeppner retweeted
We are excited to see you all— and our 145 grantees, at the @AACR Annual Meeting in New Orleans. Stop by our @AmericanCancer booth to say hello to our #cancerresearch team! #AACR22
Luke Hoeppner retweeted
public.csr.nih.gov/StudySect…
As a standing member for NIH study section, I just got an email regarding some cancer related study sections ending and new study sections planned for Oct/Nov 2022 review dates. Please plan accordingly for Re-shuffled study sections for upcoming grants.
Luke Hoeppner retweeted
If you are attending the @AACR meeting this year and you are interested in therapeutic targets to prevent therapy resistance through #plasticity and histological transformation, and to treat #SCLC tumors, don´t miss the @charlesrudin lab talks at #AACR22. #lungcancer #research
